Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial.

Fiche publication


Date publication

juin 2020

Journal

Trials

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Dr DABAKUYO-YONLI Sandrine, Dr PAGET-BAILLY Sophie, Dr DESMOULINS Isabelle, Dr MAMGUEM KAMGA Ariane


Tous les auteurs :
Mamguem Kamga A, Di Martino C, Anota A, Paget-Bailly S, Coutant C, Arveux P, Desmoulins I, Dabakuyo-Yonli TS

Résumé

Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Thus, we hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with presentation of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC.

Mots clés

Breast cancer, Compliance, Endocrine therapy, Health-related quality of life, Therapeutic information

Référence

Trials. 2020 Jun 16;21(1):527